Preferred Label : anagrelide;
MeSH note : imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis
and reduces platelet aggregation; used for thrombocythemia; structure in first source;
CISMeF synonym : BL 4162A; agrelin; agrylin; orphan brand of anagrelide hydrochloride; roberts brand of anagrelide hydrochloride; shire brand of anagrelide hydrochloride;
MeSH hyponym : imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride; 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride;
MeSH Related Number : anagrelide hydrochloride; VNS4435G39;
Related CAS MeSH : VNS4435G39 (anagrelide hydrochloride);
Is substance : O;
UNII : K9X45X0051;
Origin ID : C021139;
UMLS CUI : C0051809;
ATC code(s)
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/informations-de-securite/anagrelide-xagrid-et-generiques-risque-de-thrombose-incluant-un-infarctus-cerebral-en-cas-darret-brutal-du-traitement
2022
false
false
false
France
French
thrombosis
anagrelide
pharmacovigilance note
cerebral infarction
withdrawing treatment
---
https://www.has-sante.fr/jcms/p_3145048/fr/anagrelide
2020
false
false
false
France
administration, oral
anagrelide
thrombocythemia, essential
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
anagrelide
quinazolines
---
https://www.ema.europa.eu/medicines/human/EPAR/Anagrelide-Mylan
2018
false
United Kingdom
French
English
syndication feed
drugs, generic
anagrelide
drug approval
europe
drug interactions
pregnancy
breast feeding
Anagrelide hydrochloride 500micrograms capsule (product)
Product containing precisely anagrelide hydrochloride 1 milligram/1 each conventional
release oral capsule (clinical drug)
thrombocythemia, essential
treatment outcome
anagrelide
quinazolines
anagrelide
administration, oral
quinazolines
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/jcms/c_2755485/fr/xagrid
2017
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
anagrelide hydrochloride
anagrelide
quinazolines
---
https://www.ema.europa.eu/medicines/human/EPAR/Xagrid
2011
false
United Kingdom
French
English
syndication feed
drug approval
europe
adult
anagrelide
thrombocythemia, essential
treatment outcome
anagrelide
quinazolines
drug evaluation
anagrelide
administration, oral
quinazolines
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-06/xagrid_-_ct-_8853.pdf
http://www.has-sante.fr/portail/jcms/c_1062699/xagrid
2011
France
French
evaluation of the transparency committee
anagrelide
administration, oral
insurance, health, reimbursement
orphan drug production
thrombocythemia, essential
quinazolines
anagrelide
anagrelide
quinazolines
treatment outcome
product surveillance, postmarketing
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2009.06982/
2009
false
Switzerland
French
anagrelide
quinazolines
platelet aggregation inhibitors
thrombocytosis
quinazolines
journal article
---
http://www.meddispar.fr/medicaments/3651790
2008
France
French
quinazolines
drug prescriptions
legislation, drug
anagrelide
anagrelide
drug information
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct031926.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_400349
2005
France
French
capsules
anagrelide
administration, oral
orphan drug production
thrombocythemia, essential
anagrelide
adult
child
adolescent
aged
treatment outcome
3',5'-Cyclic-AMP phosphodiesterases
insurance, health, reimbursement
quinazolines
risk factors
quinazolines
evaluation of the transparency committee
---